However , compared with placebo , benralizumab reduced asthma exacerbation rates by 49 % ( 3.59 vs 1.82 ; P = .01 ) and exacerbations resulting in hospitalization by 60 % ( 1.62 vs 0.65 ; P = .02 ) in the combined groups .